Nuchev Pty Ltd AI Stock Analysis
Want to see AU:NUC full AI Analyst Report?
Nuchev Pty Ltd (NUC) AI Stock Analysis
Nuchev Pty Ltd
(ASX:NUC)
The stock scores at the absolute minimum of 37, reflecting a convergence of severe risks. The most significant factor is the company's rapidly deteriorating financial performance, marked by collapsing margins and accelerating cash burn that threatens its viability. This is compounded by a deeply negative technical trend and a lack of any valuation support, painting a uniformly high-risk profile with no identifiable strengths to offset the weaknesses.
Nuchev Pty Ltd (NUC) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 9.41M
- Dividend Yield
- ―
- Average Volume (3M)
- 12.56K
- Price to Earnings (P/E)
- -1.3
- Beta (1Y)
- 0.11
- Revenue Growth
- 11.96%
- EPS Growth
- -81.99%
- Country
- Australia
- Employees
- 100
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
Nuchev Pty Ltd Business Overview & Revenue Model
Company Description
Nuchev Limited functions as a specialized health and nutrition company, responsible for the production, marketing, and distribution of infant formula and various nutritional items derived from goat milk. Its products are sold to consumers across Aust...
Nuchev Pty Ltd Financial Statement Overview
Summary
Financial health is critically weak. While revenue is growing, gross margin collapsed to 12.4% in FY2026, net losses are widening, and cash burn is accelerating with free cash flow at -$6.7M. The balance sheet is under pressure from new debt and a shrinking equity base, making the current trajectory unsustainable.
Income Statement
18Very NegativeBalance Sheet
35NegativeCash Flow
10Very Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.68M | 25.68M | 22.94M | 11.34M | 8.79M | 9.72M |
| Gross Profit | 3.19M | 3.19M | 10.86M | 3.63M | 1.90M | 2.78M |
| EBITDA | -4.77M | -4.76M | -3.62M | -7.18M | -8.57M | -10.88M |
| Net Income | -7.39M | -7.39M | -3.82M | -7.32M | -8.81M | -11.11M |
Balance Sheet | ||||||
| Total Assets | 19.60M | 19.60M | 17.39M | 20.09M | 15.32M | 17.75M |
| Cash, Cash Equivalents and Short-Term Investments | 2.13M | 2.13M | 3.61M | 7.61M | 7.49M | 5.13M |
| Total Debt | 4.19M | 4.19M | 392.63K | 322.85K | 284.14K | 154.12K |
| Total Liabilities | 13.67M | 13.67M | 6.16M | 5.34M | 2.51M | 1.92M |
| Stockholders Equity | 5.93M | 5.93M | 11.23M | 14.75M | 12.82M | 15.83M |
Cash Flow | ||||||
| Free Cash Flow | -6.66M | -6.66M | -3.93M | -3.74M | -3.38M | -11.62M |
| Operating Cash Flow | -6.64M | -6.64M | -3.74M | -3.73M | -3.26M | -11.61M |
| Investing Cash Flow | -83.22K | -83.22K | -138.16K | -2.19M | -126.83K | -914.20K |
| Financing Cash Flow | 5.27M | 5.27M | -115.53K | 6.06M | 5.78M | -118.28K |
Nuchev Pty Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NUC, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 1.57 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NUC.
Nuchev Pty Ltd Peers Comparison
Overall Rating
AU:CLV76Outperform
AU:NOU49Neutral
AU:BUB48Neutral
AU:NGS46Neutral
AU:AHF41Neutral
AU:NUC37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | AUD 185.37M | 17.81 | 13.83% | 2.25% | 13.26% | 49.05% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 49Neutral | AUD 34.64M | -0.53 | 13.40% | ― | 8.82% | 55.22% | |
| 48Neutral | AUD 68.03M | -14.42 | -11.08% | ― | 9.08% | -183.87% | |
| 46Neutral | AUD 19.28M | -0.01 | -130.72% | ― | -33.05% | 94.22% | |
| 41Neutral | AUD 15.39M | -4.21 | -12.90% | ― | 0.46% | 46.48% | |
| 37Underperform | AUD 9.41M | -1.26 | -88.51% | ― | 11.96% | -81.99% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:NUC | Nuchev Pty Ltd | 0.06 | -0.10 | -62.50% | |
| AU:NOU | Noumi Limited | 0.13 | -0.01 | -3.85% | |
| AU:AHF | Australian Dairy Nutritionals Group | 0.02 | -0.02 | -48.48% | |
| AU:BUB | Bubs Australia Ltd. | 0.08 | -0.06 | -45.00% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | -0.00 | -9.09% | |
| AU:CLV | Clover Corporation Limited | 1.11 | 0.33 | 41.94% |
Nuchev Pty Ltd Corporate Events
Nuchev Director Jeff Martin to Retire After Ten Years
Nuchev Limited, an ASX-listed company, announced that director Jeff Martin will retire after ten years of service, stepping down at the conclusion of the 23 November 2026 annual general meeting. Martin chaired the Audit & Risk and People & Culture co...
Nuchev posts operating cash outflow, turns to new debt for support
Nuchev Limited reported quarterly customer receipts of $7.17 million, offset by significant outlays on product manufacturing, marketing, staff and corporate costs, resulting in a net operating cash outflow of $1.5 million for the three months to 30 S...
Nuchev Sets Date and Virtual Format for 2026 Annual General Meeting
Nuchev Limited, an Australian‑based health, nutrition and wellness products company, operates a portfolio of brands including Oli6, BioPractica and Medicine Tree, and distributes additional labels such as Brauer, Skin Physics and Rapid Loss. Its prod...
Nuchev Wins China Arbitration but Warns on Recovery of RMB9.1m Award
Nuchev Limited, an Australian-listed nutrition and wellness business, has secured a favourable final arbitration award in its long-running dispute with Hulun Buir Nouvlait Dairy in China. The conflict stemmed from a 2021 arrangement linked to Nuchev’...
Nuchev Sets Date for Virtual 2026 AGM and Director Nomination Deadline
Australian nutrition and wellness company Nuchev Limited, known for brands including Oli6®, BioPractica and Medicine Tree, distributes health products across grocery, pharmacy, practitioner, digital and selected international channels in Australia, N...
Nuchev Enters Women’s Health with Kuci Rollout Through Chemist Warehouse
Nuchev has signed an exclusive distribution agreement with Biomera Biotics to support the national rollout of the Kuci women’s health probiotic range through Chemist Warehouse, marking its entry into the women’s health segment. The science-led Kuci b...
Nuchev Outlines FY26 Corporate Governance Framework and ASX Compliance
Nuchev Limited has issued its FY26 Corporate Governance Statement, reaffirming the board’s commitment to high governance standards and regular review of its framework in line with evolving best practice. The statement outlines how the company complie...
Nuchev Refocuses Strategy on Nutrition Platform and Financial Discipline in FY26
Nuchev Limited has released its FY26 full-year results for the year ended 30 June 2026, highlighting a strategic shift towards building a broader nutrition and wellness platform. The company is now concentrating on improving conversion, margins and c...
Nuchev lifts revenue but margins and cash pressures deepen in FY26
Nuchev reported full-year 2026 group revenue of $25.7 million, up 12% on the prior year, driven by solid performance in its domestic Oli6® goat nutrition range and a growing contribution from Brauer after shifting to a broader distribution model. How...
Nuchev lifts revenue but posts deeper loss as asset backing weakens
Nuchev Limited reported a 12.0% rise in revenues from ordinary activities to $25.7 million for the year ended 30 June 2026, but its loss after tax widened sharply to $7.4 million, up 93.2% on the prior year. The group again withheld dividends, reflec...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
